Additional Relevant Details Catalyst Biosciences and Targacept merged together under to common Catalyst Biosceinces.  With this merger, Catalyst can now "pursue the clinical development of CB 813d, our improved Factor VIIa, CB 2679d/ISU 304, our improved FIX for hemophilia B, as well as preclinical programs focused on an engineered improved Factor Xa and two novel proteases for the treatment of complement-mediated disorders,” said Nassim Usman, Ph.D., President and Chief Executive Officer of Catalyst.